CA2739416C - Agents and methods for treatment of pain - Google Patents

Agents and methods for treatment of pain Download PDF

Info

Publication number
CA2739416C
CA2739416C CA2739416A CA2739416A CA2739416C CA 2739416 C CA2739416 C CA 2739416C CA 2739416 A CA2739416 A CA 2739416A CA 2739416 A CA2739416 A CA 2739416A CA 2739416 C CA2739416 C CA 2739416C
Authority
CA
Canada
Prior art keywords
pain
tat
peptide
agent
nr2b9c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2739416A
Other languages
English (en)
French (fr)
Other versions
CA2739416A1 (en
Inventor
Michael P. Belmares
J. David Garman
Peter S. Lu
Michael W. Salter
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of CA2739416A1 publication Critical patent/CA2739416A1/en
Application granted granted Critical
Publication of CA2739416C publication Critical patent/CA2739416C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2739416A 2008-09-03 2009-09-02 Agents and methods for treatment of pain Active CA2739416C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9402608P 2008-09-03 2008-09-03
US61/094,026 2008-09-03
PCT/US2009/055786 WO2010028089A2 (en) 2008-09-03 2009-09-02 Agents and methods for treatment of pain

Publications (2)

Publication Number Publication Date
CA2739416A1 CA2739416A1 (en) 2010-03-11
CA2739416C true CA2739416C (en) 2017-10-31

Family

ID=41797838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2739416A Active CA2739416C (en) 2008-09-03 2009-09-02 Agents and methods for treatment of pain

Country Status (7)

Country Link
US (3) US8324168B2 (enExample)
EP (1) EP2334315B1 (enExample)
JP (1) JP5801197B2 (enExample)
CN (1) CN102202677A (enExample)
AU (1) AU2009288088B2 (enExample)
CA (1) CA2739416C (enExample)
WO (1) WO2010028089A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
JP5801197B2 (ja) 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
JP6149226B2 (ja) * 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CA2873860A1 (en) * 2012-05-18 2013-11-21 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
TR201905787T4 (tr) * 2012-11-28 2019-05-21 Nono Inc Liyofilize TAT-NR2B9C formülasyonu.
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CN103012597B (zh) * 2012-12-31 2014-06-11 黑龙江大学 用于治疗骨质疏松症和止痛的OGP-CTx融合蛋白及编码该融合蛋白的核酸
BR112016007062A2 (pt) 2013-10-03 2017-09-12 Janssen Biotech Inc variantes de protoxina-ii e métodos de uso
CA2946378A1 (en) * 2014-04-22 2015-10-29 Q-State Biosciences, Inc. Analysis of compounds for pain and sensory disorders
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
US10048275B2 (en) 2015-03-13 2018-08-14 Q-State Biosciences, Inc. Cardiotoxicity screening methods
WO2016161100A1 (en) 2015-04-02 2016-10-06 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
US20190134150A1 (en) * 2016-04-27 2019-05-09 Biocells (Beijing) Biotech Co., Ltd. Therapeutic methods for excitatory neurotoxicity-related injuries
CN107312071B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
CN107913395B (zh) * 2016-10-10 2019-12-13 拜西欧斯（北京）生物技术有限公司 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
EP3693001A4 (en) * 2017-09-30 2021-07-07 Biocells (Beijing) Biotech Co., Ltd. PEPTIDIC COMPOSITION ALLOWING THE TREATMENT OF INJURIES RELATED TO EXCITING NEUROTOXICITY
CN109232745B (zh) * 2018-09-18 2020-02-28 深圳瑞健生物科技有限公司 一种可通过血脑屏障的多肽
CN109265557B (zh) * 2018-09-18 2019-12-24 深圳瑞健生物科技有限公司 一种齐考诺肽和tat肽的融合多肽在制备药物中的应用
CN109265558B (zh) * 2018-09-18 2019-12-24 深圳瑞健生物科技有限公司 改进型齐考诺肽在制备药物中的应用
CN109106942B (zh) * 2018-09-18 2019-11-22 深圳瑞健生物科技有限公司 一种可通过血脑屏障的多肽在制备药物中的应用
EP4393502A2 (en) * 2018-12-26 2024-07-03 Skinmed Co., Ltd. Acetylcholine receptor inhibitory peptides and uses thereof
CN111097037A (zh) * 2020-01-16 2020-05-05 刘成龙 一种psd95-pdz1/2结构域抑制剂及其应用
WO2024199436A1 (zh) * 2023-03-31 2024-10-03 青岛普美圣医药科技有限公司 具有延长的半衰期和提高的稳定性的多肽活性分子

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7760905B2 (en) 1999-06-29 2010-07-20 Digimarc Corporation Wireless mobile phone with content processing
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
CA2551190A1 (en) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
US8003609B2 (en) * 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
US20080227684A1 (en) * 2005-12-30 2008-09-18 Belmares Michael P Small Molecule Inhibitors of PDZ Interactions
GB0610868D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US20100040609A1 (en) * 2006-07-07 2010-02-18 Gorman James R Methods for preventing, postponing or improving the outcome of invasive spinal procedures
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
US20080124698A1 (en) 2006-11-28 2008-05-29 Ebensberger Jason M Virtual coatings application system with structured training and remote instructor capabilities
WO2008082889A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
ES2446292T3 (es) * 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
MX2009010757A (es) * 2007-04-06 2010-02-24 Kai Pharmaceuticals Inc Metodos de uso de compuestos de inhibidor gamma para atenuacion del dolor.
WO2008131099A1 (en) * 2007-04-19 2008-10-30 The Johns Hopkins University Biological agents active in central nervous system
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
JP5801197B2 (ja) 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
JP5848712B2 (ja) * 2009-12-11 2016-01-27 ノノ インコーポレイテッド 虚血性疾患および他の疾患を治療するための薬剤および方法

Also Published As

Publication number Publication date
US20130137641A1 (en) 2013-05-30
US9365620B2 (en) 2016-06-14
AU2009288088A1 (en) 2010-03-11
WO2010028089A2 (en) 2010-03-11
US20100062985A1 (en) 2010-03-11
EP2334315A2 (en) 2011-06-22
JP2012501973A (ja) 2012-01-26
US8748387B2 (en) 2014-06-10
CA2739416A1 (en) 2010-03-11
WO2010028089A3 (en) 2010-04-29
JP5801197B2 (ja) 2015-10-28
EP2334315B1 (en) 2023-01-18
AU2009288088B2 (en) 2014-12-04
US20150018283A1 (en) 2015-01-15
CN102202677A (zh) 2011-09-28
US8324168B2 (en) 2012-12-04
EP2334315A4 (en) 2012-08-15

Similar Documents

Publication Publication Date Title
US9365620B2 (en) Methods for treating pain
CN101678068B (zh) 不抑制n型钙通道而治疗中风和其他疾病
US9629892B2 (en) Treatment of penetrative injury to the brain
CN101072577B (zh) ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
CA2224795C (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US20050124550A1 (en) Compounds that modulate the glucagon response and uses thereof
JP2025011136A (ja) ジルコプランによる神経疾患治療
KR102449653B1 (ko) Kv1.3 칼륨 채널 길항제
KR101893473B1 (ko) 신경계 질병을 치료하는 ｎｄ２ 펩티드 및 방법
CN111225681A (zh) 方法
JPWO2017170924A1 (ja) 神経保護ペプチド
JPWO2017170926A1 (ja) 神経保護ペプチド

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140806

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250305